A new approach to improving cancer chemotherapy
(Medical Xpress) -- Chemotherapy kills tumor cells, but it also wreaks havoc on the rest of the body. A team of researchers led by Igor Roninson of the South Carolina College of Pharmacy just reported the discovery of a new class of drugs that reduces the adverse effects of cellular damage from chemotherapy.
The advance appears to be applicable to a wide range of cancers and has the potential to improve the efficacy of and increase the time of remission after chemotherapy. It may also be developed into a promising new therapy for age-related diseases, such as Alzheimers.
Conventional anticancer drugs, while essential for current cancer therapy, have side effects that can damage healthy cells and cause them to promote the growth of surviving cancer cells, said Roninson, the SmartState Endowed Chair of Translational Cancer Therapeutics at the South Carolina College of Pharmacy, who has appointments with both the University of South Carolina and the Medical University of South Carolina. We needed to find a way to interrupt that process.
The cancer-supporting activity of conventional drugs appears to occur, in part, because these drugs damage both tumor cells and the patients normal tissues, causing numerous changes in drug-damaged cells, including the onset of senescence. Cellular senescence, or aging, can result from changes in the chromosomes that develop with age, or it can be induced by DNA damage caused by traditional anticancer drugs and other factors. The senescent cells and other damaged cells have been shown to produce cancer-supporting molecules as well as proteins implicated in other diseases of old age, such as Alzheimers disease and arthritis.
The importance of these secretory activities of senescent cells has been convincingly demonstrated in recent studies, but no practical method for blocking this pattern was previously known. Roninsons team has just reported in the Proceedings of the National Academy of Sciences the development of Senexin A, the first of a series of chemicals that inhibit the secretory pattern of the senescent and other damaged cells. This inhibition is key to reducing the cancer-promoting effects of chemotherapy.
In one of the experiments reported, carried out by co-author Hippokratis Kiaris at the University of Athens (Greece), mice were treated with a commonly used anticancer drug. After the mice recovered from this treatment, both drug-treated and untreated mice were injected with cancer cells.
Strikingly, mice pretreated with the anticancer drug developed tumors much more efficiently than the untreated mice. Furthermore, the blood of mice pretreated with the anticancer drug had a higher content of proteins that stimulate the growth of tumor cells.
But treating mice with Senexin A neutralized the cancer-supporting effects of the anticancer drug, blocking the increase both in the tumor growth and in the production of tumor supporting growth factors. Senexin A also increased the antitumor effectiveness of the conventional drug.
The molecular target of Senexin A was identified as a protein kinase (an enzyme that modifies other proteins by adding a phosphate) called CDK8 (cyclin-dependent kinase 8). Senexin A is the first selective inhibitor of CDK8 and its nearest relative, CDK19. CDK8 is involved in the regulation of gene expression; that is, the changing in the balance of proteins produced in a cell. Unlike better known kinases of the CDK family, CDK8 does not have a role in the process of cell division.
CDK8 was already known to play an important role in colon cancer and melanoma. The team reported a striking correlation between the gene expression of CDK8 and the duration of relapse-free survival in patients with breast and ovarian cancer. For example, breast cancer patients with below-median expression of CDK8 survived without the disease approximately seven years longer than patients who had above-median expression of CDK8. The new results implicate CDK8 in damage- and senescence-induced production of cancer-supporting proteins, and suggest that the new class of drugs may provide benefit in many different types of cancer.
The research represents a collaboration between Senex Biotechnology (a Columbia, S.C., company founded by Roninson), USC, and the University of Athens (Greece), together with several other institutions. The study was based on Roninsons discovery in 2000 that p21, a protein that stops the division of damaged and aging cells, induces the production of multiple proteins implicated in cancer, Alzheimers and other aging-related diseases. The team has now demonstrated that p21, which was known to inhibit other members of the CDK family, in contrast, promotes the activity of CDK8 and stimulates CDK8-regulated genes.
Journal reference: Proceedings of the National Academy of Sciences
Provided by South Carolina College of Pharmacy
- Researchers make major breakthrough in melanoma research Dec 22, 2010 | not rated yet | 0
- Cell senescence does not stop tumor growth Jan 19, 2012 | not rated yet | 0
- Abcc10 may be effective in extending the effectiveness of anticancer drugs May 16, 2011 | not rated yet | 0
- Match your treatment to your cancer Jun 30, 2011 | not rated yet | 0
- Gene therapy kills breast cancer stem cells, boosts chemotherapy Sep 12, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be a term called "intestinal metaplasia" of stomach
16 hours ago Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
- More from Physics Forums - Medical Sciences
More news stories
The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...
Cancer 4 hours ago | not rated yet | 0
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
Cancer 5 hours ago | not rated yet | 0
A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...
Cancer 6 hours ago | not rated yet | 0
A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...
Cancer 7 hours ago | not rated yet | 0
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
Cancer 9 hours ago | not rated yet | 0
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
11 hours ago | 4.2 / 5 (5) | 0 |
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
9 hours ago | 4.9 / 5 (9) | 0 |
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
5 hours ago | 3 / 5 (2) | 0
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
6 hours ago | 5 / 5 (3) | 0 |
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
11 hours ago | 4.4 / 5 (5) | 0 |
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
7 hours ago | not rated yet | 0 |